IOVA News and Press, Iovance Biotherapeutics Inc. From 02/20/24

2024-02-20 11:02:33 ET Shares of Iovance Biotherapeutics (NASDAQ: IOVA) had skyrocketed by 33.8% as of 10:39 a.m. ET Tuesday. The huge gain came after the company announced on Friday that the Food and Drug Administration (FDA) had granted accelerated approval for Amtagvi (lefileucel...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is one today's most active stocks by volume. So far today, approximately 30.63M shares of Iovance Biotherapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 6.4M shares. Iovance Biotherapeutics, Inc., a clinical-stage biot...

2024-02-20 07:30:00 ET Summary Iovance Biotherapeutics' stock has increased over 50% since September, following positive news about its TIL therapy for advanced melanoma. The FDA has granted approval for Iovance's TIL therapy, named Amtagvi, for the treatment of advanced melanoma ...

2024-02-20 07:07:59 ET More on Iovance Biotherapeutics Iovance: Approval For Historic Solid Tumor Targeting TIL Therapy Likely, Outlook Promising Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date Iovance Biotherapeutics: The Ea...

SAN CARLOS, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) t...

2024-02-17 23:32:56 ET Iovance Biotherapeutics (NASDAQ: IOVA) stock price has rebounded this year and is hovering at its highest point since October 2022. It has risen by over 120% as investors focus on the upcoming earnings report that is scheduled on Friday. Iovance earnings ahead...

2024-02-16 15:52:13 ET DENVER, Colo., Feb 16, 2024 (www.247marketnews.com)- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) announced, a few minutes ago, that the U.S. Food and Drug Administration approved its AMTAGVI (lifileucel) suspension for intravenous infusion. AMTAGVI is a tum...

SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and li...

2024-02-16 15:38:18 ET More on Iovance Biotherapeutics Iovance: Approval For Historic Solid Tumor Targeting TIL Therapy Likely, Outlook Promising Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date Iovance Biotherapeutics: The Ea...

AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells that recognize and fight cancer SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NE...